Captopril

Generic Name: Captopril

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₅NO_₃S

CAS Number: 62571-86-2

Unique Ingredient Identifier: 9G64RSX1XD

Background: Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension.

Indication: For the treatment of essential or renovascular hypertension (usually administered with other drugs, particularly thiazide diuretics). May be used to treat congestive heart failure in combination with other drugs (e.g. cardiac glycosides, diuretics, β-adrenergic blockers). May improve survival in patients with left ventricular dysfunction following myocardial infarction. May be used to treat nephropathy, including diabetic nephropathy.

Associated Conditions: Aldosteronism, Anatomic renal artery stenosis, Congestive Heart Failure (CHF), Diabetic Nephropathy, Heart Failure, Hypertension, Hypertensive crisis, Non-STEMI Acute Coronary Syndrome, Raynaud's Phenomenon, Ejection fraction of 40% or less Left ventricular dysfunction

Clinical Trials

Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure

Phase 4

Completed

Conditions: Preeclampsia

Interventions: Drug: CLONIDINE
Drug: CAPTOPRIL

First Posted Date: 2013-01-07

Last Posted Date: 2013-07-29

Lead Sponsor: Instituto Materno Infantil Prof. Fernando Figueira

Target Recruit Count: 90

Registration Number: NCT01761916

Locations: 🇧🇷
IMIP, Recife, Pernambuco, Brazil

Measurement of Eye Blood Flow and Renal Function in Healthy and Diabetic Patients

Phase 1

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Captopril
Drug: placebo

First Posted Date: 2012-06-22

Last Posted Date: 2019-08-01

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 24

Registration Number: NCT01626469

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Increased Renal Oxygenation and Angiotensin Converting Enzyme Inhibition

Phase 4

Completed

Conditions: Renal Disease

Interventions: Drug: captopril 25mg

First Posted Date: 2012-03-06

Last Posted Date: 2012-03-06

Lead Sponsor: Instituto de Cardiologia do Rio Grande do Sul

Target Recruit Count: 5

Registration Number: NCT01545479

A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis

Phase 3

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Placebo
Drug: CP690,550
Drug: CP-690,550

First Posted Date: 2011-10-25

Last Posted Date: 2017-05-18

Lead Sponsor: Pfizer

Target Recruit Count: 593

Registration Number: NCT01458574

Locations: 🇺🇸
Springhill Memorial Hospital (Endoscopy Only), Mobile, Alabama, United States
🇺🇸
Hope Square Surgical Center, Rancho Mirage, California, United States
🇺🇸
GI Consultants, Atlanta, Georgia, United States

and more 268 locations

Shigella Sonnei OSPC-rDT Conjugate Vaccine

Phase 1

Withdrawn

Conditions: Shigellosis

First Posted Date: 2011-07-21

Last Posted Date: 2017-07-02

Lead Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Registration Number: NCT01399424

Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure

Phase 1

Terminated

Conditions: Hypertension
Pure Autonomic Failure
Multiple System Atrophy

Interventions: Drug: Losartan
Drug: Captopril
Drug: Placebo

First Posted Date: 2011-02-09

Last Posted Date: 2018-08-24

Lead Sponsor: Vanderbilt University

Target Recruit Count: 12

Registration Number: NCT01292694

Locations: 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States

Use of Telmisartan and Captopril in Inflammation of Hemodialysis Patients

Phase 4

Completed

Conditions: Inflammation
End-stage Renal Disease

Interventions: Drug: Telmisartan plus Captopril
Drug: captopril plus placebo
Drug: Placebo
Drug: telmisartan plus placebo

First Posted Date: 2011-01-06

Last Posted Date: 2018-12-19

Lead Sponsor: Coordinación de Investigación en Salud, Mexico

Target Recruit Count: 60

Registration Number: NCT01271478

Locations: 🇲🇽
Hospital de Especialidades, CMNO, IMSS, Guadalajara, Jalisco, Mexico

A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: CP 690,550 5 mg
Drug: CP 690,550 10 mg
Biological: Etanercept 50 mg
Other: Placebo

First Posted Date: 2010-11-16

Last Posted Date: 2018-12-26

Lead Sponsor: Pfizer

Target Recruit Count: 1101

Registration Number: NCT01241591

Locations: 🇦🇹
Krankenhaus Hietzing mit Neurologischem Zentrum Rosenhuegel, Wien, Austria
🇧🇪
Cliniques universitaires Saint-Luc, Bruxelles, Belgium
🇧🇦
Department for skin and venerial diseases, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina

and more 117 locations